GGrantIndex
← Search

NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER

$18,813,807U10FY2014CANIH

Nrg Oncology Foundation, Inc., Philadelphia PA

Investigators

Linked publications, trials & patents

Trial NCT07554573Trial NCT07504588Trial NCT07441681Trial NCT07198074Trial NCT07195734Trial NCT07166406Trial NCT07097142Trial NCT07061977Trial NCT06958328Trial NCT06770582Trial NCT06580314Trial NCT06568172Trial NCT06500481Trial NCT06500455Trial NCT06393751Trial NCT06388018Trial NCT06169124Trial NCT06126276Trial NCT06029270Trial NCT05950464Trial NCT05946213Trial NCT05879926Trial NCT05705401Trial NCT05624996Trial NCT05554354Trial NCT05554328Trial NCT05538897Trial NCT05438212Trial NCT05408845Trial NCT05327686Trial NCT05295589Trial NCT05276973Trial NCT05256225Trial NCT05174169Trial NCT05112601Trial NCT05095376Trial NCT05053152Trial NCT05050162Trial NCT05050084Trial NCT04852887Trial NCT04739800Trial NCT04729959Trial NCT04588246Trial NCT04533750Trial NCT04513717Trial NCT04458909Trial NCT04402788Trial NCT04396860Trial NCT04391049Trial NCT04333537Trial NCT04214067Trial NCT04158141Trial NCT04134260Trial NCT04105374Trial NCT04095364Trial NCT04068103Trial NCT04037254Trial NCT04034927Trial NCT03997370Trial NCT03952585Trial NCT03914612Trial NCT03811002Trial NCT03801902Trial NCT03801876Trial NCT03738228Trial NCT03737994Trial NCT03660826Trial NCT03602586Trial NCT03371719Trial NCT03367702Trial NCT03348631Trial NCT03274687Trial NCT03258554Trial NCT03217266Trial NCT03199885Trial NCT03188393Trial NCT03186898Trial NCT03180502Trial NCT03180268Trial NCT03137771Trial NCT03070886Trial NCT03018249Trial NCT02997228Trial NCT02921256Trial NCT02839707Trial NCT02775812Trial NCT02728258Trial NCT02713386Trial NCT02502266Trial NCT02498600Trial NCT02488967Trial NCT02466971Trial NCT02446600Trial NCT02364557Trial NCT02316548Trial NCT02315430Trial NCT02311920Trial NCT02257528Trial NCT02254278Trial NCT02206334

Abstract

DESCRIPTION (provided by applicant): NRG Oncology is a newly constituted NCI National Clinical Trials Network (NCTN) network group created through the coordinated efforts of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) with a primary vision of improving the lives of adult patients with localized or locally advanced malignancies through the conduct of high quality NCI-supported multi-institutional clinical trials. NRG Oncology (or NRG) has leveraged the tremendous resources, leadership, membership, and history of practice-defining research of the three legacy groups to create a modern clinical and translational research organization with the capability to execute clinical and translational research trials for adult patients with common and rare malignancies in the following disease sites: Gynecologic Cancer (including Ovarian, Cervix and Endometrial Cancer); Brain Tumors (Primary and Secondary); Breast Cancer; Gastrointestinal Cancers (Colorectal and Non-Colorectal Cancers); Genitourinary Cancer; Head and Neck Cancer; and Lung Cancer. NRG will be the leading network group defining new standards of care and scientific paradigms for several of these disease sites. For these seven cancer disease sites, NRG will primarily conduct trials for patients with early or intermediate stage cancers testing innovative diagnostic and therapeutic approaches, including novel imaging, radiation oncology, and surgical approaches; the integration of novel systemic agents or classes of systemic agents with optimized loco-regional therapies and existing systemic therapies, and the use of biomarker- and biologic pathway-defined approaches to risk stratification, investigational therapy assignment, and clinical trial decision-making. The group has seven scientific core committees and four integrated committees which provide both scientific support and generate protocols: Developmental Therapeutics (DT), Translational Science, Patient-Centered Outcomes Research, and Cancer Prevention and Control Committees. NRG's DT Committee builds on the GOG DT Committee's success in enrolling over 500 patients/year on early phase trials leading to phase III trials. The NRG Operations Center is fully aligned with NRG Oncology Statistical and Data Management Center (SDMC) and the NRG Biorepositories and will be fully compliant with all NCI regulations and proactive in improving the efficiency and quality of its research. The group will serve as a scientific resource for other NCTN network groups for radiation oncology innovation through its Center for Innovative Radiation Oncology (CIRO).

View original record on NIH RePORTER →
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER · GrantIndex